Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$1.73
+1.2%
$1.70
$0.77
$14.00
$7.02M1.485.06 million shs139,362 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$1.60
-30.4%
$2.31
$1.41
$13.20
$2.11M0.54176,310 shs3.47 million shs
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
$34.62
-0.3%
$1.90
$1.44
$8.18
$24.24M0.13935,975 shs300 shs
MYOS
MYOS RENS Technology
$3.35
$0.74
$3.85
$16.70M1.081.68 million shsN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$0.16
$0.15
$0.12
$1.52
$2.50M1.281.62 million shs112,297 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
+0.59%-26.29%+26.67%+37.90%-80.84%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
+27.37%+16.92%+6.54%+10.68%-75.09%
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
-0.27%-0.01%-2.37%-2.49%+1,680.62%
MYOS
MYOS RENS Technology
0.00%0.00%0.00%-50.18%+409.10%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.63%-4.82%+14.29%-4.88%-84.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.2066 of 5 stars
0.02.00.00.02.60.80.6
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
1.0063 of 5 stars
3.33.00.00.00.60.00.6
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.5817 of 5 stars
3.53.00.00.00.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.50
Moderate Buy$21.001,212.50% Upside
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.00
Buy$3.251,926.18% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$2.46 per shareN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$420K5.03N/AN/A$0.57 per share2.81
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
$10K2,423.67N/AN/A$1.26 per share27.48
MYOS
MYOS RENS Technology
$1.03M0.00N/AN/A$0.13 per share0.00
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.27M0.19N/AN/A$1.72 per share0.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/A
MYOS
MYOS RENS Technology
-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$5.15M-$0.97N/AN/AN/A-41.24%-58.93%-26.92%6/19/2024 (Estimated)

Latest SNOA, EYEG, ADIL, CYCC, and MYOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/19/2024Q4 2023
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$6.35-$6.23+$0.12-$6.23N/A$0.03 million
2/8/202412/31/2023
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.21-$0.06+$0.15-$0.04N/A$3.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
N/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A

Latest SNOA, EYEG, ADIL, CYCC, and MYOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/28/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.15724/1/20244/2/20244/5/2024
2/29/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.14863/1/20243/4/20243/7/2024
1/31/2024
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
Monthly$0.14762/1/20242/2/20242/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
4.90
4.90
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
0.91
0.91
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
0.01
3.07
3.07
MYOS
MYOS RENS Technology
0.11
3.78
1.94
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
4.07
3.11

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
44.06 million3.47 millionNo Data
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2,0181.32 million1.21 millionOptionable
AB Corporate Bond ETF stock logo
EYEG
AB Corporate Bond ETF
14700,0005.28 millionNot Optionable
MYOS
MYOS RENS Technology
1512.19 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
915.61 million14.17 millionNot Optionable

SNOA, EYEG, ADIL, CYCC, and MYOS Headlines

SourceHeadline
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
finanznachrichten.de - April 9 at 10:39 AM
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
accesswire.com - April 9 at 7:30 AM
Sonoma Pharmaceuticals Reports Recent Publication…Sonoma Pharmaceuticals Reports Recent Publication…
pharmiweb.com - April 4 at 10:28 AM
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsSonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
accesswire.com - April 4 at 7:30 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
finanznachrichten.de - March 28 at 9:52 PM
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
accesswire.com - March 28 at 4:01 PM
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsSonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
accesswire.com - March 27 at 7:30 AM
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - February 10 at 2:56 PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
finance.yahoo.com - February 8 at 4:32 PM
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseSonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
finance.yahoo.com - January 23 at 9:51 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finanznachrichten.de - November 13 at 5:52 PM
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finance.yahoo.com - November 13 at 5:52 PM
Sonoma Pharmaceuticals Inc SNOASonoma Pharmaceuticals Inc SNOA
morningstar.com - November 11 at 10:31 PM
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceSonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
finance.yahoo.com - November 3 at 8:49 AM
US Stocks Mixed; Bristol Myers Posts Upbeat EarningsUS Stocks Mixed; Bristol Myers Posts Upbeat Earnings
benzinga.com - October 26 at 6:54 PM
Crude Oil Down 2.5%; Mastercard Posts Upbeat EarningsCrude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
markets.businessinsider.com - October 26 at 6:54 PM
Dow Dips Over 100 Points; US GDP Growth Tops ExpectationsDow Dips Over 100 Points; US GDP Growth Tops Expectations
benzinga.com - October 26 at 1:54 PM
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockSonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 1:54 PM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 10:20 PM
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 5:19 PM
macOS Sonoma now available: Heres whats newmacOS Sonoma now available: Here's what's new
pocketnow.com - September 29 at 3:54 PM
macOS SonomamacOS Sonoma
macrumors.com - September 28 at 12:39 PM
Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?
stuff.tv - September 14 at 7:13 AM
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
finance.yahoo.com - August 15 at 10:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals logo

Adial Pharmaceuticals

NASDAQ:ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals

NASDAQ:CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
AB Corporate Bond ETF logo

AB Corporate Bond ETF

NASDAQ:EYEG
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

MYOS RENS Technology

NASDAQ:MYOS
MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

NASDAQ:SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.